Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA4 | P22748 | 2/20 | 0.33 |
| ▸ | CA5A | P35218 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 2/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.33 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.32 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13799210 | 0.78 | KCNA3 (0.33) | ALDH1A1MAPTKCNA3KCNA5TSHR | |
| SCHEMBL13799234 | 0.73 | ALDH1A1 (0.32) | ALDH1A1MAPTKCNA3KCNA5 | |
| SCHEMBL13799227 | 0.66 | USP2 (0.37) | MAPTKDM4EMAPK1 | |
| SCHEMBL13799205 | 0.64 | KMT2A (0.40) | ALDH1A1MAPTLMNACA12KDM4E | |
| SCHEMBL14264177 | 0.63 | TDP1 (0.44) | ALDH1A1MAPTLMNAKCNA3KCNA5 | |
| SCHEMBL13799231 | 0.61 | MAPT (0.35) | ALDH1A1MAPTKDM4EHPGDMAPK1 | |
| SCHEMBL28782607 | 0.60 | DPP4 (0.54) | P2RX3ALDH1A1MAPTLMNAKDM4E | |
| SCHEMBL31129949 | 0.60 | ALDH1A1 (0.51) | ALDH1A1MAPTLMNATSHRMEN1 | |
| SCHEMBL13799209 | 0.60 | ALDH1A1 (0.45) | ALDH1A1MAPTLMNACA12KDM4E | |
| SCHEMBL14264184 | 0.60 | CYP19A1 (0.34) | ALDH1A1MAPTKCNA3KCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149417-A1 | Methods and compositions for the treatment of cancer using benzopyrone-type PARP inhibitors | BIPAR SCIENCES, INC. | 2009-06-11 | — | — | US | disclosed |
| US-20090149417-A1 | Methods and compositions for the treatment of cancer using benzopyrone-type PARP inhibitors | BIPAR SCIENCES, INC. | 2009-06-11 | — | — | US | disclosed |
| US-20080076778-A1 | METHODS FOR DESIGNING PARP INHIBITORS AND USES THEREOF | BIPAR SCIENCES, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| US-20080076778-A1 | METHODS FOR DESIGNING PARP INHIBITORS AND USES THEREOF | BIPAR SCIENCES, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| WO-2008030887-A2 | METHODS FOR DESIGNING PARP INHIBITORS AND USES THEREOF | BIPAR SCIENCES, INC. (US) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149417-A1 | Methods and compositions for the treatment of cancer using benzopyrone-type PARP inhibitors | PARP1, PARP2, PARP3 | P2RX3 1054/4885ALDH1A1 674/4885MAPT 3550/4885 |
| US-20080076778-A1 | METHODS FOR DESIGNING PARP INHIBITORS AND USES THEREOF | PARP3, PARP1, PARP15 | P2RX3 3150/4885ALDH1A1 1787/4885MAPT 3488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.